ViiV Healthcare broadens reach & scope of PACF response to mother-to-child transmission of HIV
Published 12-15-10
Submitted by ViiV Healthcare
ViiV Healthcare today announced a new request for grant proposals for the Positive Action for Children Fund. The Positive Action for Children Fund was established in 2010 with an initial commitment of £50 million over 10 years to support programmes focused on preventing HIV transmission from mother-to-child, and to better the health and well being of women and vulnerable children around the globe. Such work is closely aligned with the World Health Organization's vision for addressing the mother-to-child transmission of HIV and works toward achieving the Millennium Development Goals set to reduce child mortality and improve maternal health. This new call aims to stimulate grassroots community action in support of global PMTCT community efforts to eliminate mother-to-child transmission of HIV.
Earlier this year, the Positive Action for Children Fund awarded a total of £3.6m in grants to support 12 projects focused on preventing HIV transmission from mother-to-child, to improve the health and wellbeing of women, children and their families around the globe. This new call for proposals aims to support a broader mix of organisations with a focus on the priority issues in the priority countries to address mother-to-child transmission of HIV. In particular we have identified 14 priority countries for PMTCT interventions: Nigeria, Democratic Republic of Congo, Uganda, Ethiopia, Cameroon, Mozambique, Zimbabwe, Zambia, Malawi, Angola, Burundi, Chad, Tanzania and India.
"The health of women and children affected by HIV in the countries hardest hit by the epidemic remains one of the most critical areas of unmet need that the community faces today," commented Dr. Dominique Limet, CEO, ViiV Healthcare. "The commitment of the PACF is to create a breadth and depth of new opportunities to support mothers and children in countries most in need."
AIDS has become a leading cause of illness and death among women of reproductive age in countries with a high burden of HIV infection. More than 1000 children become infected with HIV every day, during the perinatal and breast feeding period, according to the UNAIDS global report published last November. In spite of recent progress in the Prevention of Mother-to-Child Transmission (PMTCT), in sub Saharan Africa children account for more than 10% of all HIV infections. This is in stark contrast with countries such as the UK, where because of optimal treatment, management and prevention strategies, mother-to-child transmission of HIV has reduced from 25% to less than 1% (Townsend 2008) and continues to improve1.
"This new call for proposals for the Positive Action for Children Fund presents a unique opportunity to foster innovation and support a broader range of projects and interventions in the communities where the need is greatest. We are hopeful that these new criteria will help organisations identify which projects and proposals have the best chance of success with the fund as they apply. It should also enable us to help a broader range of different types of community groups - creating a new community of organisations fighting together to support women in making informed choices, preventing the transmission of HIV to babies and helping children and their families currently living with HIV," said Professor Catherine Peckham, Chair of the Positive Action for Children Advisory Board.
About the Call for Proposals
The Fund will now operate three funding 'windows' as outlined below.
The deadline for core grants concept notes is 4th March, 2011.
The deadline for small grants proposals is 11th February, 2011.
The deadline for these proposals is 11th February, 2011.
To find out more about how to apply for any of these windows, and to apply, link to: http://www.viivhealthcare.com/community/positive-action-for-children-fund/grant-criteria-and-application.aspx
About the Positive Action for Children Fund
The Positive Action for Children Fund was first announced in July 2009 and builds upon the foundation of the long-standing Positive Action programme, established in 1992. With an emphasis on community engagement, ViiV Healthcare's Positive Action programme will continue to support global efforts to address the challenges of HIV prevention, tackling stigma and discrimination, building capacity and treatment literacy.
Following extensive consultations with some of the sector's leading non-governmental organisations, practitioners and policy-makers in this field, the Fund focuses on grants that pursue the four elements of the World Health Organization's (WHO) strategic vision and comprehensive approach for addressing the mother-to-child transmission of HIV, under these four headings:
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established by GlaxoSmithKline (LSE: GSK.L) and Pfizer (NYSE: PFE) to deliver advances in treatment and care for people living with HIV. Our aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and then take a new approach to deliver effective and new HIV medicines as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline and commitment, please visit www.viivhealthcare.com.
UK Media enquiries: | Rebecca Hunt | (020) 8380 6275 | |
Claire Brough | (020) 8047 5502 | ||
US Media enquiries: | Marc Meachem | (919) 483 2839 | European Analyst/Investor enquiries: | Sally Ferguson | (020) 8047 5543 |
Gary Davies | (020) 8047 5503 | ||
US Analyst/Investor enquiries: | Tom Curry | (215) 751 5419 | |
Jen Hill Baxter | (215) 751 7002 |
Notes for editors
About the Positive Action for Children Fund Board
The independent Fund Board membership is drawn from the global HIV sector and community with strong representation from sub-Saharan Africa. The Board meets at least annually to consider project funding under agreed programme areas and funding priorities. Membership comprises the following representatives:
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined in October 2012. The company's aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.
For more information on the company, its management, portfolio, pipeline and commitment, please visit www.viivhealthcare.com.
More from ViiV Healthcare